Gonadotropin-releasing hormone agonist use in men without a cancer registry diagnosis of prostate cancer

Table 4 Predictors of lack of a diagnosis of prostate cancer in the SEER tumor registries among incident GnRH agonist users

			Model 1^a		Model 2^b
Variable	Category	Distribution (%)	Odds Ratio	95% CI	Odds Ratio	95% CI
Year of diagnosis	1993	11.5	1.00		1.00
	1994	11.8	1.35	(0.59,3.10)	1.34	(0.58,3.09)
	1995	11.6	0.88	(0.35,2.19)	0.88	(0.35,2.20)
	1996	13.6	1.13	(0.49,2.61)	1.14	(0.49,2.65)
	1997	15.5	0.78	(0.33,1.88)	0.81	(0.34,1.95)
	1998	16.9	0.85	(0.37,1.98)	0.89	(0.38,2.07)
	1999	19.2	0.91	(0.41,2.04)	0.96	(0.43,2.17)
Age at diagnosis (years)	67 – 74	46.3	1.00		1.00
	≥75	53.7	1.38	(0.89,2.15)	1.24	(0.79,1.95)
Ethnicity	White	83.0	1.00		1.00
	Black	9.6	1.30	(0.66,2.58)	1.23	(0.62,2.46)
	Other	7.4	0.67	(0.27,1.65)	0.68	(0.28,1.68)
Region	West	46.3	1.00		1.00
	Northeast	14.8	0.86	(0.46,1.60)	0.84	(0.45,1.57)
	Midwest	31.1	0.51	(0.29,0.91)	0.46	(0.26,0.83)
	South	7.8	0.78	(0.36,1.71)	0.79	(0.36,1.72)
Comorbidity Index	0	71.4	1.00		1.00
	≥1	28.6	1.60	(1.03,2.48)	1.55	(1.00,2.41)
Zip education	< 12.5%	25.7	1.00		1.00
(% adult < 12 years education)	≥12.5%	74.3	1.24	(0.68,2.28)	1.24	(0.68,2.26)
Procedures within 3 months before or after diagnosis
Hospitalization		21.2			1.48	(0.79,2.79)
Transurethral resection of prostate		8.4			0.19	(0.05,0.68)
Prostate Biopsy		77.9			0.59	(0.33,1.06)
Transrectal Ultrasound		58.7			0.96	(0.57,1.62)
Radical Prostatectomy		4.5			0.51	(0.13,2.00)
Radiation Therapy		17.1			0.27	(0.10,0.72)
CT scan/MRI pelvis		36.3			1.08	(0.63,1.85)
Bone scan		62.6			0.86	(0.52,1.44)

^aMultivariable logistic regression model with presence or absence of a diagnosis of prostate cancer in SEER as the dependent variable, and year of diagnosis, patient age, race, SEER region of residence, comorbidity index, and educational status entered as independent variables
^bMultivariable logistic regression model with presence or absence of a diagnosis of prostate cancer in SEER as the dependent variable, and the variables from Model 1 with the addition of the listed diagnostic procedures entered as independent variables
GnRH; Gonadotropin-releasing hormone
SEER; Surveillance, Epidemiology and End-Results

ISSN: 1472-6963